For research use only. Not for therapeutic Use.
CL2A-SN-38(CAT: I018024) is a conjugate of the cytotoxic drug SN-38 and a chemical linker called 3-(2-chloroethyl)-2,3-dimethylmaleic anhydride (CL2A). SN-38 is an active metabolite of the chemotherapy drug irinotecan, which is used to treat a variety of cancers, including colon, lung, and ovarian cancer. However, SN-38 has poor solubility and a narrow therapeutic index, which limits its clinical use. By conjugating SN-38 to CL2A, CL2A-SN-38 is created, which can target and bind to tumor cells, leading to the selective release of SN-38 in the tumor microenvironment. This increases the therapeutic efficacy of SN-38 while reducing the risk of systemic toxicity. CL2A-SN-38 has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential treatment for various types of cancer.
| Catalog Number | I018024 |
| CAS Number | 1279680-68-0 |
| Molecular Formula | C₇₃H₉₇N₁₁O₂₂ |
| Purity | ≥95% |
| Reference | [1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. |
| Documentation | CoA |
